Axovant highlights a carefully crafted comment by Dr Hampel:
""Results of our recently published brain imaging studies add to the growing amount of clinical and scientific evidence that supports the importance of the cholinergic system in the treatment of Alzheimer's disease. Hopefully, we will soon get additional innovative compounds and therapies that will further enhance the cholinergic brain system. Companies like Axovant and others are in the late-stage development process of such novel compounds. If they are successful with the development of these compounds, then we believe they could be used in combination with standard of care therapies that we have today. That's really good news for patients and caregivers," said Dr. Hampel, Professor at the Department of Neurology, Marie Curie University and AXA Research Fund Excellence Chair (Sorbonne Universities), and representative of the Hippocampus Study."
I don't find any direct relation between Dr Hampel and Axovant, however, he does sit on the SAB of Anavex. His comment appears to protect that association while under Axovant's hedgified spotlight. (chuckles)
Dr. Hampel had this to say about A2-73:
“The collective data from this Phase 2a trial supports the concept of targeting the sigma-1 receptor with ANAVEX 2-73 with a degree of confidence that we did not foresee. Sigma-1 receptor presents an innovative interventional upstream approach to impact key cellular events believed to contribute to Alzheimer’s disease pathophysiology. The presented Phase 2a data underlines the importance of rigorously investigating a potential efficacy signal on co-primary outcomes such as cognition and function in larger and well-powered trials”.
And most recently giving the nod to other indications:
“ANAVEX 2-73’s specific molecular biology, combined with its observed favorable safety and tolerability profile makes it a very interesting candidate to explore in further clinical trials of different neurological diseases.”
Little Orphan Annievex has her support.
§
